The firm advised Biocidin Botanicals, a pioneer in botanical based nutrition products, in its acquisition by CoreCell Biosciences, an emerging industry leading manufacturer and distributor of dietary supplements intended for foundational health benefits. This partnership will allow the companies to deepen its shared mission of bringing hope and health to patients navigating today's complex health landscape. Financial terms were not disclosed.
The Sheppard Mullin deal team was led by partner and Private Equity team co-leader Ariel Yehezkel and included special counsel Vincent Buehler, associates Matthew Greenberg and Patrick Hao, and partners Josh McLane and Dmitriy Chelnitsky. This is the latest transaction the firm has completed in this space, including representing US Pharma Lab's sale to Biofarma Group to create the first global CDMO focused on nutraceuticals and advising CellCore BioSciences in its sale to Kainos Capital.
Click here to read more.